May 2022

HepatoPredict: improved & better environmental footprint.

After a lot of under the hood work, we are happy to announce Version 2.0 of the HepatoPredict kit, more

New ambition, new image!

Ophiomics was founded in 2015 as clinical testing laboratory. In 2020, with the support of the EIC Accelerator grant and

Going global @ArabHealth

Ophiomics @ Arab Health 2023

🚀Off to #ArabHealth2023 with the #EUeic Overseas Trade Fairs ✈️Programme 2.0! Pay us a visit at the European Pavilion (Za’abeel Hall 6 – Booth Z6.C25).

Ethics training @ Ophiomics

Ethics training at Ophiomics

Ophiomics secures Series A investment

Ophiomics secured a Series A investment round to support commercial development and continued technical/clinical development of its flagship product HepatoPredict,

in the news

https://ec.europa.eu/research-and-innovation/en/horizon-magazine/silent-killer-liver-cancer-prompts-race-improve-organ-replacements

Ophiomics @ 4th meeting of Translational Hepatology

Discussing translational research in Liver Cancer, in particular the role of SMEs in IVD development.

Ophiomics @ Precision Medicine Forum (PT)

Presenting HepatoPredict and discussing the development of new precision medicine solutions

Ophiomics @ PT GI cancer meeting

We presented HepatoPredict to an assembly of GastroEnterologists, Oncologists, Surgeons and other medical professionals in the Portuguese GI cancer meeting

Ophiomics @ European Congress of Pathology

Ophiomics attending the European Congress of Pathology (ECP) Ophiomics is attending ECP from 3-7 of September in Basel, Switzerland. We are

HepatoPredict first clinical validation published in Annals of Surgery

Our paper “A gene expression signature to select hepatocellular carcinoma patients for liver transplantation” is finally out and can be

Navigation:

Home
Products
R&D
News
Careers
Contacts
MyOphiomics

Search here:

Search

Legal menu:

Quality Policy
Privacy Policy

Back to top Drag